NCT07373236Completed
The Effect of Endogenous GLP-1 on Glucagon Secretion in Type 1 Diabetes
Examining the Effect of Endogenous Glucagon-like Peptide-1 on Glucagon Secretion in Type 1 Diabetes
Source: ClinicalTrials.gov · Last updated 29 Apr 2026
Brief summary (registry, in English)
Type 1 diabetes is a serious and burdensome disease that carries the risk of severe complications and premature death, partly due to low blood sugar, also called hypoglycaemia. This is a constant threat, as individuals with type 1 diabetes lack the body's natural safeguard against low blood sugar: the hormone glucagon, which is normally released from the pancreas. Recent research in mice suggests that this missing safeguard may be due to an imbalance in the hormones released from different cells in the pancreas. More specifically, glucagon-like peptide-1 (GLP-1) appears to play a role in the lack of glucagon secretion. By blocking this hormone using the substance exendin(9-39)NH₂, normalization of glucagon release during low blood sugar has been observed in mice with type 1 diabetes. The present study aims to investigate whether the same mechanism applies in humans with type 1 diabetes. If confirmed, this finding could form the basis for a novel adjunct treatment to insulin therapy and thereby potentially reduce the risk of hypoglycaemia in this patient group.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 12 (actual)
- First submitted
- 20 Nov 2025
- Start date
- 23 Jan 2026
- Primary completion date
- 9 Apr 2026
- Lead sponsor
- Asger Lund, MD
- Diseases
- Type 1 diabetes
- NCT number
- NCT07373236
What you commit to
- Study type: Interventional
- Participants enrolled: 12
- From 23 Jan 2026 to the primary completion date, 9 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Liver disease (Evaluated by alanine aminotransferase (ALAT) and/or aspartate aminotransferase (ASAT) \>2 times normal values) or a history of hepatobiliary disorder
- Active or recent (within 5 years) malignant disease
- Any condition considered incompatible with participation by the investigators.
Lab values
- Anaemia (haemoglobin below normal range)
- Kidney disease (serum creatinine above normal range)
- Treatment with any glucose-lowering drugs beside insulin
Other
- Late microvascular complications except mild non-proliferative retinopathy
- Regular tobacco smoking or use of other nicotine-containing products
Who the study is looking for
- Caucasian ethnicity
- Age between 18 and 70 years
- T1D (diagnosed according to the criteria of the World Health Organization) with HbA1c \<69 mmol/mol (\<8.5%)
- Body mass index between 19 and 30 kg/m2
- T1D duration of 2-30 years
- C-peptide negative (5 gram arginine-stimulated C-peptide ≤100 pmol/l)
- Treatment with a stable basal-bolus or insulin pump regimen for ≥3 months
Age in the registry: 18 years to 70 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Gentofte Hospital Coordinator of this site? Confirm its status | Hellerup | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.